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ABSTRACT: Delivery systems have been developed to
address problematic properties of drugs, but the specific release
of drugs at their targets is still a challenge. Polymers that
depolymerize end-to-end in response to the cleavage of stimuli-
responsive end-caps from their termini, commonly referred to
as self-immolative polymers, offer high sensitivity to stimuli and
have potential for the development of new high-performance
delivery systems. In this work, we prepared hybrid particles
composed of varying ratios of self-immolative poly(ethyl
glyoxylate) (PEtG) and slowly degrading poly(D,L-lactic acid) (PLA). These systems were designed to provide a dual release
mechanism consisting of a rapid burst release of drug from the PEtG domains and a slower release from the PLA domains. Using
end-caps responsive to UV light and reducing thiols, it was found that triggered particles exhibited partial degradation, as
indicated by a reduction in their dynamic light-scattering count rate that depended on the PEtG:PLA ratio. The particles were
also shown to release the hydrophobic dye Nile red and the drug celecoxib in a manner that depended on triggering and the
PEtG:PLA ratio. In vitro toxicity assays showed an effect of the stimuli on the toxicity of the celecoxib-loaded particles but also
suggested it would be ideal to replace the sodium cholate surfactant that was used in the particle synthesis procedure in order to
reduce the background toxicity of the delivery system. Overall, these hybrid systems show promise for tuning and controlling the
release of drugs in response to stimuli.
■ INTRODUCTION
The controlled release of therapeutics using drug delivery
systems has been studied in depth over the last several
decades.1−3 Drug delivery systems can provide improved
solubility or dispersibility of hydrophobic drugs, improved
bioavailability, and more specific targeting, leading to fewer
adverse side effects. Polymers have been widely explored for
drug delivery, as they can be engineered to assemble into a
variety of nanostructures such as vesicles, micelles, and solid-
core particles by tuning both their chemical structures and their
processing conditions.4,5 Polymeric solid-core particles, com-
posed of a hydrophobic polymer core that is stabilized in
aqueous solution using a surfactant coating, are among the
most widely investigated drug delivery systems due to their ease
of preparation by various techniques such as emulsification or
nanoprecipitation.6−8 A hydrophobic cargo molecule can be
encapsulated within the hydrophobic cores of the particles
during their preparation.
Thus far, most polymeric particles have been composed of
biodegradable polyesters such as poly(lactic acid), poly(glycolic
acid), poly(caprolactone), and their copolymers.9−11 While
these have been effective at improving the delivery of
therapeutics, the hydrolytic degradation of polyesters is
inherently a random process, and it is challenging to control
its rate.12 In some cases, degradation may be more rapid than
desired, while in other cases it may be too slow. To address this
limitation, stimuli-responsive particles have been developed and
shown to release drug molecules in response to stimuli such as
heat, reactive oxygen species, reducing agents, or changes in
pH.13,14
Over the past decade, a new class of stimuli-responsive
polymers was introduced. Often termed self-immolative
polymers (SIPs), these polymers undergo complete end-to-
end depolymerization in response to stimuli-mediated cleavage
of end-caps from the polymer termini.15,16 This offers the
potential to amplify responses to stimuli, making SIPs of
significant interest for a wide range of applications including
sensors,17−19 responsive plastics and coatings,20−22 lithogra-
phy,23 and drug delivery.18,24−28 Backbones including poly-
carbamates,17,24 polyaldehydes,20,23,29−34 polycarbonates,35 pol-
ythiocarbamates,36 and poly(benzyl ether)s37 have been
developed, and end-caps responsive to stimuli including
light,25,26,31 thiols,26,36 acid,38 fluoride,20,21,39 heat,40,41 and
H2O2
19,42 have been studied.
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Only a few studies thus far have explored the potential of
SIPs for drug delivery. Our group demonstrated the triggered
release of Nile red as a model drug from assemblies composed
of poly(ethylene glycol) (PEG) block copolymers with a
polycarbamate SIP based on 4-hydroxybenzyl alcohol and N,N-
dimethylethylene diamine.24 Almutairi and co-workers prepared
nanoparticles from the same polymer backbone capped with a
UV light-responsive end-cap and studied the release of Nile red
from these particles in response to UV and two-photon
irradiation.25 Liu and co-workers reported self-immolative
vesicles based on polycarbamates composed of 4-aminobenzyl
alcohol as the hydrophobic block and demonstrated vesicle
disruption and the release of payloads including fluorophores,
enzymes, and the drugs camptothecin and doxorubicin (Dox)
in response to light or reducing conditions as stimuli.26 They
also prepared amphiphilic hyperbranched polycarbamate−PEG
copolymers and demonstrated the release of Dox that was
covalently bound to the polymers as well as DNA that was
complexed to cationic poly(2-(dimethylamino)ethyl methacry-
late) chains conjugated to the periphery of the hyperbranched
polymer.18 Vallet-Regi, Manzano, and co-workers used
polycarbamates as blocking agents to control drug release
from mesoporous silica nanoparticles.28 Despite this progress,
the release of potentially toxic quinone methides and aza-
quinone methides from these systems during their depolyme-
rization is a possible drawback.43 To address this, we recently
reported the study of micelles based on poly(ethyl glyoxylate)
(PEtG)−PEG block copolymers.27 PEtG depolymerizes to
ethyl glyoxylate, which is subsequently hydrolyzed to generate
ethanol and glyoxylic acid (Figure 1a). Glyoxylic acid is a
metabolic intermediate that can be processed in the liver and
should be nontoxic in low concentrations.44 Previous work has
demonstrated the nontoxicity of PEtG degradation products in
a Caenorhabditis elegans (invertebrate) model.45 We demon-
strated that by simple tuning of the end-cap linker molecule
between the PEG and PEtG blocks it was possible to easily
change the stimulus to which the micelles responded, and the
triggered release of doxorubin and curcumin was demon-
strated.27
We describe here an alternative approach for formulating
drug delivery systems using PEtG. Using an emulsion method,
we prepared sodium cholate-stabilized PEtG particles.
Furthermore, in order to add an additional level of control
over the drug release, we explored particles composed of blends
of PEtG and poly(D,L-lactic acid) (PLA). It was envisioned that
triggering of PEtG degradation would result in erosion and
rapid drug release from the PEtG domains, leaving drug-loaded
PLA for a sustained drug release. 6-Nitroveratryl carbonate-
capped PEtG was selected for its rapid responsiveness to UV
light and served as an ideal model system.31 Disulfide-capped
PEtG38 was selected as a thiol-sensitive system, as elevated
concentrations of reducing agents such as glutathione (GSH)
are associated with the intracellular environment as well as
hypoxic tumor tissue.46,47 The degradation of these hybrid
particles in response to UV light and thiols was studied by
dynamic light scattering (DLS) and the release of Nile red as a
probe. The drug celecoxib was encapsulated in the hybrid
particles, and its stimuli-responsive release was explored. Initial
in vitro experiments were performed to explore the behavior of
the system in cells.
■ RESULTS AND DISCUSSION
Preparation and Characterization of PEtG and PEtG−
PLA Blends. PEtGs with different end-caps (Figure 1b) were
synthesized as previously reported,31,38 and the characterization
data for the specific batches used here are included in the
Supporting Information. PEtG with a 6-nitroveratryl carbonate
end-cap (PEtG-NVOC) was selected because the NVOC can
be easily and cleanly removed using UV light.27,31 Although UV
light is not practical for most in vivo applications, this serves as a
valuable model. PEtG with a disulfide end-cap (PEtG-disulfide)
was selected because it can be triggered using reducing thiols
via an initial reduction of the disulfide, followed by cyclization
of the resulting thiol to produce a cyclic thiocarbonate,
releasing uncapped PEtG.38 Increased concentrations of the
reducing agent glutathione are found in intracellular compart-
ments and in hypoxic tumor tissue, potentially allowing for the
selective release of drugs in these environments.48,49 A control
PEtG had a benzyl carbonate end-cap (PEtG-BnCO) that was
not expected to be specifically responsive to stimuli but
contained the same carbonate linkage to the PEtG terminus as
the other polymers.31
In addition to the pure polymers, blends of PLA with the
PEtGs were also studied. Ratios of 9:1, 7:3, and 1:1 PEtG:PLA
were prepared. Lower ratios of PEtG:PLA were not explored
because it was anticipated that they would exhibit primarily
nonstimuli-responsive behavior. They were prepared by
codissolving the polymers in CH2Cl2. After removing the
solvent, the blends were characterized by thermogravimetric
analysis (TGA) and differential scanning calorimetry (DSC).
These experiments utilized PEtG-NVOC, which behaves very
Figure 1. (a) Depolymerization scheme for PEtG. (b) Chemical
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similarly to the other PEtGs in terms of its thermal properties.38
TGA showed that in agreement with the literature pure PLA
was stable up to ∼300 °C (Figure 2a).50 Pure PEtG with the
NVOC end-cap was stable up to 200 °C, also in agreement
with the reported value.31 PEtG is less thermally stable than
PLA due to its susceptibility to depolymerize. A two-step
thermal degradation was observed for each of the three blends,
and the mass fractions lost in each step were consistent with the
relative ratios of polymers in the blends. DSC analysis showed
that the two polymers were mostly phase separated in the
blends as distinct glass transition temperatures (Tg) were
observed for each of PEtG and PLA (Figure 2b, Table S2).
However, the increase in the PEtG Tg from −8 to −1 °C and
simultaneous decrease in the PLA Tg from 46 to 40 °C as the
PEtG content decreased to 50% suggested that some degree of
mixing between the two polymers also occurred.
Particle Preparation. Particles were prepared by an
emulsion−evaporation procedure. Various parameters includ-
ing the surfactant identity, surfactant and polymer concen-
tration, and sonication time were investigated with the aim of
preparing particles of each polymer blend composition with
diameters less than 200 nm and acceptable (<0.3) polydisper-
sity indices (PDI), to allow potential in vivo circulation. Using
PEtG−NVOC, it was found that using sodium cholate at 5 mg/
mL in H2O, PEtG at 10 mg/mL in CH2Cl2, a 10:1 ratio of
H2O:CH2Cl2, and three 30 s periods of sonication it was
possible to prepare particles with Z-average diameters ranging
from 128 to 144 nm and PDIs ranging from 0.11 to 0.26 as
measured by DLS (Figure 3a, Table 1). While a relatively high
mass ratio of 5:1 sodium cholate:polymer was used to stabilize
the emulsion of small droplets during the preparation, after
dialysis purification of the particles it was found that the ratio
was ∼1.5:1. No significant trends were observed regarding the
effects of the PEtG:PLA ratio. TEM imaging confirmed that the
particles all had solid spherical morphologies (Figure 3b−f).
The diameters observed by TEM were smaller than those
measured by DLS, which can likely be attributed to the dried
versus hydrated states of the particles in these different analyses
as well as to possible aggregation in suspension. This procedure
was also applied to blends of PEtG−disulfide and PEtG−BnCO
with PLA, and the sizes and PDIs were very similar (Figures
S4−S5, Tables S3−S4). The stabilities of the pure PEtG−
NVOC and pure PEtG−disulfide particles were also studied in
mouse serum over 48 h at 37 °C. The particles underwent a
gradual increase in diameter over the course of the experiment,
suggesting some degree of interactions with proteins and
possible aggregation, but were relatively stable for the first
several hours (Figures S6−S7).
Triggered Particle Degradation. First, DLS was used to
study the degradation of the particles in response to stimuli.
The DLS count rate is proportional to both the number of
scattering particles in suspension and their mass if the
attenuator of and laser position are fixed at constant values.
A decrease in either the mass or number of particles arising
from degradation would lead to a reduction in the count rate.
Keeping the attenuator fixed, the count rate was measured
initially and then at time points after introduction of the stimuli.
For the PEtG−NVOC particles, the stimulus was the
application of 2.8 mW/cm2 of light radiation for 30 min, as
we have previously found this irradiation time to be sufficient to
achieve complete end-cap cleavage for other systems at similar
concentration.27,31 For PEtG−disulfide particles, 7.7 mM
dithiothreitol (DTT) was added as a reducing agent, as this
concentration was effective in triggering the depolymerization
of assemblies based on PEtG block copolymers.27 Control
experiments involved the application of stimuli to non-
responsive PEtG−BnCO control particles to account for any
nonspecific effects of the stimuli as well as background
degradation.
For particles with each ratio of PEtG−NVOC:PLA, there
was a rapid decrease in count rate over the first hour following
UV irradiation that likely corresponded to degradation (Figure
4a). In addition, there were plateaus in the count rates at
percentages corresponding approximately to the percentage of
PLA in the particles. Pure PEtG particles approached zero
counts at the 24 h time point; 9:1 PEtG−NVOC:PLA particles
degraded to ∼10% of their original count rate and then
remained constant; 7:3 PEtG−NVOC:PLA particles plateaued
at ∼30% of the initial count rate; and 50 wt % of PLA particles
plateaued at ∼50% of the initial count rate. Examination of the
Z-average diameter and PDI for a representative pure PEtG−
NVOC particle sample showed large fluctuations in diameter
and an increase in PDI, consistent with a major disruption of
the particles (Table S5). In contrast, the diameter and PDI of
1:1 PEtG−NVOC:PLA particles underwent only minor
fluctuations, suggesting that the particles were still largely
intact due to the remaining PLA (Table S6). Light scattered
from the pure PLA particles remained constant at 100% of the
original counts over the 24 h period, suggesting that the system
was stable over this time period. Furthermore, the application
of UV light to the control PEtG−BnCO:PLA particles did not
lead to any significant changes in count rate, demonstrating the
specificity of the stimulus.
Figure 2. Thermal characterization data for PEtG-NVOC, PLA, and
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As observed in our previous work with PEtG−PEO block
copolymer assemblies,27 the reduction in count rate occurred
more slowly for the PEtG−dilsulfide:PLA systems in response
to DTT (Figure 4b). This may result from the reduction
reaction being slower than the photochemical end-cap cleavage.
In addition, DTT is likely only able to react with end-caps at
the particle surface, whereas UV light can penetrate the
particles to some extent. Again, the particles with higher PEtG
content exhibited larger reductions in the count rate over the
experiment in general, corresponding to more complete
degradation. Both pure PEtG−dilsulfide and 1:1 PEtG−
disulfide:PLA particles underwent only minor fluctuations in
Z-average diameter and PDI, suggesting that even while PEtG
was eroded, resulting in a decrease in count rate, there were still
particles remaining at 48 h (Tables S7−S8). The count rates
from the pure PLA particles and all of the PLA:PEtG-BnCO
particles remained near 100% of their original values over 48 h.
The particle degradation was also studied using a fluorescent
probe. Nile red is a hydrophobic dye that is highly fluorescent
in hydrophobic environments but undergoes aggregation and
fluorescence quenching in water.51,52 Therefore, Nile red
encapsulated within the particles fluoresces, and as it is released
into the surrounding aqueous environment, the fluorescence
decreases. Nile red was encapsulated using the same particle
preparation method described above except that 1 wt % of Nile
Figure 3. (a) DLS intensity distributions for particles prepared from PEtG−NVOC and PLA. (b−f) TEM images of particles prepared from PEtG−
NVOC and PLA: (b) pure PEtG; (c) 9:1 PEtG:PLA; (d) 7:3 PEtG:PLA; (e) 1:1 PEtG:PLA; and (f) pure PLA.
Table 1. Z-Average Diameters and PDI Values Measured by
Dynamic Light Scattering for Particles Prepared from
PEtG−NVOC and PLA
blend Z-average diameter (nm) PDI
pure PEtG 144 ± 13 0.19 ± 0.07
9:1 PEtG:PLA 137 ± 19 0.26 ± 0.11
7:3 PEtG:PLA 128 ± 7 0.11 ± 0.03
1:1 PEtG:PLA 133 ± 8 0.12 ± 0.03
pure PLA 132 ± 10 0.13 ± 0.04
Figure 4. Count rate as a function of time after application of stimulus
for: (a) particles composed of PEtG−NVOC:PLA or controls PEtG−
BnCO:PLA, where the stimulus was UV light and (b) particles
composed of PEtG−disulfide:PLA or controls PEtG−BnCO:PLA,
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red relative to polymer was incorporated into the CH2Cl2
phase. The initial fluorescence intensity was measured for each
sample, and then UV light and DTT were applied as stimuli to
PEtG−NVOC:PLA, PEtG−disulfide:PLA, and PEtG−BnCO:-
PLA particles as described above, and the fluorescence was
measured over 24 h. PEtG−NVOC:PLA particles exhibited a
significant burst release of Nile red within the first hour after
being exposed to UV light (Figure 5a). This can be attributed
to the PEtG fraction of the particles being degraded. Similar to
the DLS study, the fluorescence plateaued at higher percentages
of the initial fluorescence as the PLA content of the particles
increased. This suggests that it may be possible to selectively
release a payload from the PEtG phase of the particles, while
retaining the load in the PLA phase. After application of light to
PEtG−BnCO:PLA particles, small reductions in the Nile red
fluorescence were observed. This could be attributed to some
background degradation of these systems, such as hydrolysis of
the carbonate linkage between the end-cap and polymer, which
would induce depolymerization. However, based on the DLS
results described above, it likely corresponds to the passive
diffusion of some Nile red from the peripheries of the particles
or other factors that would alter the environment of Nile red.
As observed in the DLS study, Nile red release from the
PEtG−disulfide:PLA particles following application of DTT
was slower than for the light-responsive particles (Figure 5b).
Again, this can likely be attributed to slower end-cap cleavage.
However, this experiment also suggested that the extent of Nile
red release was dependent on the PLA content. The levels of
release from the PEtG−BnCO:PLA particles treated with DTT
were similar to those observed following UV irradiation of the
same particles. Overall, the DLS and Nile red release data show
that it is possible to trigger degradation of the particles
specifically by matching the stimulus with the end-cap and that
it appears possible to trigger different percentages of
degradation by tuning the PLA content in the particles.
Drug Loading and Triggered Release. Celecoxib was
selected as an initial drug for investigating loading and release.
It is a widely used nonsteroidal anti-inflammatory and has
shown potential in cancer therapy.53,54 However, it exhibits low
aqueous solubility and adverse gastrointestinal and cardiac
effects when administered systemically.55,56 It was loaded into
PEtG−NVOC:PLA, PEtG−disulfide:PLA, and PEtG−BnCO:-
PLA particles during their preparation by the addition of 30 wt
% of drug relative to polymer in the CH2Cl2 phase of the
emulsion. Unloaded drug was removed by filtration and
dialysis. The loading efficiencies ranged from 17 to 33% and
the drug content from 4.9 to 8.8 wt %. However, there were no
statistically significant differences between the loadings of the
different PEtG:PLA ratios (Table S9). The particle diameters
were very similar to those of the unloaded particles described
above (Tables S10−S12, Figures S8−S10).
Celecoxib release in response to UV light and DTT was
investigated for the PEtG−NVOC:PLA and PEtG−disulfide:-
PLA systems, respectively, with the absence of stimuli and the
application of stimuli to 100% PEtG−BnCO:PLA particles
serving as controls. Initially, measurement of the released
celecoxib posed a significant challenge due to the low water
solubility of this drug. Upon application of the stimuli, the
scattering of the suspension clearly decreased, indicative of
degradation, but at the same time, the celecoxib precipitated
(Figure S11). Due to this precipitation, use of a protocol
involving dialysis into buffer resulted in measurement of the
precipitated drug’s dissolution rate rather than its actual release.
The addition of Polysorbate 20, which we have used
successfully with celecoxib in other studies in our lab, resulted
in rapid release from control systems, suggesting that it
destabilized the particles. Thus, the released and precipitated
drug was instead centrifuged, dissolved in CH3CN, and then
quantified by UV−visible spectroscopy based on its absorbance
at 253 nm.
Application of UV light as a stimulus to the PEtG−NVOC
systems resulted in a rapid release of celecoxib (Figure 6a). The
percentage of released drug ranged from 15 to 82% in the first
30 min, depending on the PEtG−NVOC:PLA ratio. Over the
first 4 h, 26−89% of celecoxib was released. It is possible that
the remaining ∼10% of the drug in the case of the pure PEtG−
NVOC system can be solubilized by the sodium cholate
surfactant in the system. The percentage of drug released
depended on the PEtG:PLA ratio, with higher PEtG content
generally leading to increased drug release. However, more
release was observed for the 1:1 system than for the 7:3 system,
and the reason for this is not clear. Less release was observed
from pure PLA particles (Figure 6a), controls consisting of
nonirradiated PEtG−NVOC:PLA or UV-irradiated particles
composed of PEtG−BnCO:PLA (Figure 6b). Interestingly, the
irradiated particles generally had higher release than the
nonirradiated particles, suggesting the possibility of a non-
specific reaction involving UV light. However, this was not
observed in the DLS or Nile red experiments.
The addition of DTT to the PEtG−disulfide systems also
resulted in the rapid release of celecoxib with similar trends
Figure 5. Fluorescence of the encapsulated hydrophobic probe Nile
red as a function of time after application of stimulus for: (a) particles
composed of PEtG−NVOC:PLA or control PEtG−BnCO:PLA,
where the stimulus was UV light and (b) particles composed of
PEtG−disulfide:PLA or control PEtG−BnCO:PLA, where the
stimulus was DTT. The error bars correspond to standard deviations.
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observed with respect to the PEtG:PLA ratio as for the PEtG−
NVOC systems (Figure 6c). However, consistent with the DLS
and Nile red studies, this release was slower than for the UV
light-triggered release, with 7−44% of celecoxib released over
the first 4 h and 32−80% released over 24 h, again suggesting
end-cap cleavage as the rate-limiting step. Again, control PLA
particles (Figure 6c), PEtG−disulfide:PLA without DTT added
and PEtG−BnCO:PLA (Figure 6d) with DTT added, exhibited
slower release than the triggered systems. Nevertheless, the
level of release from the control systems appeared to be
relatively high, ranging from 18 to 49% over 4 h in the UV light
experiment and 21−46% over 24 h in the DTT experiment. For
this reason, we assessed the composition of the precipitated and
centrifuged material from the 4 and 24 h time points by
dissolving it in CD3CN and analyzing it by
1H NMR
spectroscopy (Figures S12−S20). By comparison of the spectra
with those of celecoxib, PLA, and PEtG, it was found that after
application of DTT to the PEtG−disulfide:PLA particles the
pellet was primarily composed of celecoxib and not polymer,
confirming its release from the particles and effective isolation
by centrifugation. On the other hand, the pellets obtained from
PEtG−disulfide:PLA particles not exposed to DTT or PEtG−
BnCO:PLA particles exposed to DTT contained mostly intact
PEtG and PLA, indicating that some drug-loaded particles were
destabilized and isolated during the centrifugation procedure,
resulting in apparent release percentages for the controls that
are likely higher than the true celecoxib release rates. Thus, the
true leakage rates of celecoxib from the untriggered particles are
likely lower than those reflected in Figures 6b and 6d.
Nevertheless, this was still the most effective protocol to
measure and demonstrate the triggered release of celecoxib
from these systems and the ability to tune the release profile by
tuning the PLA content.
In Vitro Studies. As noted above, celecoxib has been shown
to exhibit anticancer properties, and there is value in releasing
anticancer drugs specifically in cancer cells in order to mitigate
the side effects that can result from their systemic
administration.53 Therefore, the MDA-MB-231 breast cancer
cell line was selected to evaluate the toxicities of different
particles in both the absence and presence of stimuli using a 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. This study focused on the systems composed
of pure PEtG rather than blends with PLA, in order to
maximize the effect of the stimuli.
Following a 48 h incubation of the drug with cells, free
celecoxib was found to have an IC50 value of ∼30 μg/mL in this
cell line (Figure 7a). When celecoxib-loaded PEtG−NVOC
particles were incubated with the cells for 48 h in the absence of
any stimuli, they were found to be somewhat less toxic than the
free drug, with an IC50 value near the maximum concentration
studied of ∼75 μg/mL (concentration of loaded drug). On the
other hand, when celecoxib-loaded PEtG−NVOC particles
were incubated with the cells for 24 h (to allow uptake into
cells), irradiated with 360 nm light (LED flashlights, 90 mW/
cm2) for 15 min, and then incubated an additional 24 h, the
IC50 was reduced to ∼30 μg/mL, similar to that of free
celecoxib. This is consistent with the release of drug from the
system. It should be noted that cells exposed to 360 nm light,
Figure 6. Celecoxib release as a function of time from (a) PEtG−NVOC:PLA particles irradiated with UV light; (b) PEtG−NVOC:PLA particles
not triggered with UV light (non-irr) and control PEtG−BnCO:PLA particles irradiated with UV light (irr); and (c) PEtG−disulfide:PLA particles
treated with DTT; (d) PEtG−disulfide:PLA particles not treated with DTT (no DTT) and control PEtG−BnCO:PLA particles treated with DTT
(DTT). The error bars correspond to standard deviations.
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but no particles, did not exhibit any significant reduction in
metabolic activity relative to nonirradiated cells, showing that
this short irradiation process did not alone lead to toxicity. The
toxicity of PEtG−NVOC particles without drug was also
studied. The particles began to exhibit some toxicity at
concentrations of 500 μg/mL and above (Figure 7c). Initially
this was surprising as the PEtG and its degradation products
were expected to be benign. However, when we studied the
toxicity of the free sodium cholate, the surfactant used to
stabilize the particles, we found that it began to cause toxicity at
∼300 μg/mL (Figure 7d). Based on mass recovery studies, we
found that our particles were composed of ∼1.5:1 mass ratio of
sodium cholate:PEtG. Therefore, despite cholic acid being one
of the major bile acids produced in the liver, in this assay it is
likely that most of the toxicity arose from the sodium cholate.
In addition, based on the drug loading of ∼8 wt % for the
PEtG−NVOC system (1000 μg/mL of PEtG−NVOC needed
to deliver 80 μg/mL of celecoxib), some of the toxicity arising
from the nonirradiated celecoxib-loaded PEtG−NVOC system
(Figure 7a) likely resulted from the delivery system itself (due
to the cholate). The effect of the UV light would perhaps be
larger were this not the case.
The PEtG−disulfide system was studied in a similar manner,
except that in this case the reducing agent glutathione (10 mM)
was added as the stimulus following 24 h of incubation, and
then the system was incubated for an additional 24 h. As for the
PEtG−NVOC system, the triggered system and free celecoxib
had similar IC50 values of ∼30 μg/mL, while the celecoxib-
loaded PEtG−disulfide without GSH added had a somewhat
higher IC50 value of ∼60 μg/mL (Figure 7b). Thus, it appears
that the GSH has a modest effect.
■ CONCLUSIONS
Blends of PLA with self-immolative PEtG were studied for the
preparation of drug delivery particles. UV light-responsive,
thiol-responsive, and nonresponsive control end-caps were
used. Thermal studies suggested that PEtG and PLA were
mainly phase separated, as Tg values of both blocks were
observed using DSC. Using an emulsification−evaporation
procedure with sodium cholate as a surfactant, we prepared
particles with diameters of 130−150 nm. Upon application of
the appropriate stimuli, the PEtG portions of the particles
degraded, resulting in partial degradation of the systems as a
function of the PEtG:PLA ratio. Using Nile red as a fluorescent
probe and celecoxib as a drug, it was demonstrated that the
triggered PEtG depolymerization could be used to release a
portion of the loaded drug, leaving the remaining drug
encapsulated in the PLA phase. The fraction of rapidly released
drug could be tuned based on the PEtG:PLA ratio. Celecoxib-
loaded PEtG particles with UV light and thiol-responsive end-
caps were investigated in MDA-MB-231 breast cancer cells.
Triggering of these systems with their corresponding stimuli in
the presence of cells led to toxicities similar to that of free
celecoxib and somewhat higher than the corresponding
untriggered systems. However, differences between the
triggered and untriggered systems were reduced by some
background toxicity of the systems at high concentrations that
likely results from the sodium cholate surfactant. In the future,
Figure 7. Metabolic activities, measured by MTT assays, of MDA-MB-231 cells following 48 h exposure to varying concentrations of (a) free
celecoxib compared with celecoxib encapsulated in PEtG−NVOC particles without stimulus or with UV light applied for 15 min at 24 h; (b) free
celecoxib compared with celecoxib encapsulated in PEtG−disulfide particles without stimulus or with 10 mM glutathione added at 24 h; (c) particles
composed of either PEtG−NVOC or PEtG−disulfide without drug; and (d) sodium cholate. The error bars correspond to standard deviations.
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this limitation can be mitigated by changing the surfactant,
increasing the drug loadings, or using a more potent drug that
requires less drug and vehicle to achieve the desired biological
effect.
■ METHODS
General Materials and Procedures. PEtG−NVOC (Mn =
70 kg/mol, Đ = 2.4), PEtG−BnCO (Mn = 56 kg/mol, Đ = 1.6),
and PEtG−disulfide (Mn = 24 kg/mol, Đ = 1.4) were prepared
as previously reported.31,38 Their molar mass data were
obtained from size exclusion chromatography (SEC) in THF
at 1 mL/min using a Viscotek GPC Max VE2001 solvent
module equipped with a Viscotek VE3580 RI detector
operating at 30 °C, two Agilent Polypore (300 × 7.5 mm)
columns, and a Polypore guard column (50 × 7.5 mm). A
calibration curve was obtained using polystyrene standards.
Sodium cholate hydrate, GSH, DTT, Nile red, and PLA (18−
28 kg/mol) were obtained from Sigma-Aldrich. Celecoxib was
purchased from Ontario Chemicals, Inc. TGA was performed
on a Q50 from TA Instruments at a heating rate of 10 °C/min
from 35 to 500 °C under a nitrogen atmosphere. DSC was
performed using a Q2000 from TA Instruments (New Castle,
DE). The heating/cooling rate was 10 °C/min from −75 to
+120 °C. Data were obtained from the second heating cycle.
Fluorescence spectra were obtained using a QM-4 SE
spectrometer from Photon Technology International equipped
with double excitation and emission monochromators. UV−
visible spectra were obtained on a Varian UV/vis Cary 300
spectrophotometer. Ultrapure water was obtained from a
Barnstead EASYpure II system. Spectra/Por regenerated
cellulose membranes were used for dialysis. 0.22 μm Acrodisc
Syringe Filters (nonpyrogenic) with 13 mm diameter were used
to filter particle suspensions for analysis. DLS was performed
using a Zetasizer Nano ZS instrument from Malvern Instru-
ments at 25 °C at a concentration of 0.1 mg/mL of polymer
assemblies. The Z-average diameter and PDI index for each
series of particles were measured in triplicate. TEM imaging
was done using a Phillips CM10 microscope operating at an
acceleration voltage of 80 kV with a 40 μm aperture. An
amount of 20 μL of particle suspension (1.0 mg/mL) was
placed on a copper grid, and the excess liquid was wicked off
with a Kimwipe. The resulting sample was air-dried for 24 h
before imaging.
Preparation of PLA−PEtG Blends. Blends of 9:1, 7:3, and
1:1 PEtG:PLA were prepared by combining 9.0, 7.0, and 5.0 mg
of PEtG with 1.0, 3.0, or 5.0 mg of PLA, respectively. These
polymer samples were then dissolved in CH2Cl2 (1 mL) and
stirred for 30 min to allow for complete mixing of the polymers.
The solvent was removed in vacuo for analyses.
Preparation of Particles. PEtG, PLA, or PEtG:PLA blend
(10 mg) was dissolved in CH2Cl2 (1 mL). A separate solution
of sodium cholate (50 mg) was prepared in distilled water (10
mL). The organic phase was added to the aqueous phase in a
20 mL glass vial. The sonication amplitude was set to 10%
intensity on a Branson 450 Digital Sonifier. The biphasic
mixture was then sonicated for three 30 s intervals with 10 s
breaks in between for a total of 90 s of sonication over 120 s.
To the resulting emulsion, a magnetic stir bar was added, and
the solution was vigorously stirred overnight (16 h) to
evaporate the organic phase. After evaporation of the organic
phase, the particle suspension was dialyzed (3500 g/mol
molecular-weight cutoff (MWCO) dialysis membrane, 8 h)
against distilled water to remove any excess sodium cholate or
trace organic solvent.
Particle Degradation Studied by DLS. Particles were
prepared as described above, with the exception that the
resulting suspensions were dialyzed against 100 mM, pH 7.4
phosphate buffer (1 L, 24 h, water changed once at ∼12 h).
The final polymer concentration was diluted to ∼0.1 mg/mL.
The count rate was measured by DLS while fixing the
attenuator at 7 (t = 0 reading). For PEtG−NVOC and the
PEtG−BnCO control, irradiation with UV light was performed
in an ACE Glass photochemistry cabinet containing a mercury
light source (450 W bulb, 2.8 mW/cm2 of UVA radiation) for
30 min. A t = 30 min count rate measurement was obtained.
Then the samples were incubated at 37 °C in the dark, and the
DLS count rate was measured at additional time points over 24
h. For PEtG−disulfide and the PEtG−BnCO control, DTT
(7.7 mmol) was added, and then the samples were incubated at
37 °C in the dark. The DLS count rate was measured at various
time points over 24 h. Control experiments without stimulus
were also included in each case. Each experiment was
performed in triplicate.
Loading and Triggered Release of Nile Red. Nile-red-
loaded PEtG, PLA, or PEtG:PLA particles were prepared by the
addition of Nile red (0.1 mg) to the CH2Cl2 solution of PEtG
or PEtG:PLA. The solution was stirred for several hours to
ensure complete mixing, and then the particle preparation was
performed as described above. The resulting suspensions were
dialyzed against 100 mM, pH 7.4 phosphate buffer. The
suspensions were then diluted 10-fold in the same buffer. Using
an excitation wavelength of 540 nm, the initial emission
intensity of Nile red was measured at 602 nm to obtain
fluorescence at T0 (starting time). At this point, the
appropriate stimuli (UV light for PEtG−NVOC and DTT for
PEtG−disulfide) were applied as described above for the DLS
study, and the suspensions were placed in a 37 °C oven.
Fluorescence measurements were taken at time points over a
24 h period. By comparing the fluorescence at each time point
with its initial fluorescence, the percent initial fluorescence was
calculated. These measurements were taken in triplicate.
Preparation of Celecoxib-Loaded Particles. Particles
were prepared as described above with the addition of celecoxib
(30 wt %, 3.0 mg, 7.9 μmol) dissolved in the CH2Cl2 phase
with the polymer mixtures before sonication. After evaporation
of the organic phase, the particle suspension was filtered
through a pipet containing a cotton filter to remove any
unloaded drug crystals. The resulting suspension was further
dialyzed (3500 g/mol molecular-weight cutoff (MWCO)
dialysis membrane, 16 h) against distilled water (1 × 1 L) to
remove excess sodium cholate and any soluble free drug.
Afterward, 0.1 mL of the particle suspension was diluted with
1.4 mL of acetonitrile. The absorbance of the resulting solution
was measured by UV−visible spectroscopy at 253 nm. The
concentration was calculated based on a celecoxib calibration
curve (ε = 16 400 L/mol·cm, acetonitrile, 253 nm), and the
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Release of Celecoxib from Particles. Celecoxib-loaded
particles in pH 7.4 buffer were prepared as described above. An
initial absorbance measurement was taken by removing 200 μL
of each sample and dissolving it in 1 mL of acetonitrile.
Insoluble buffer salts were removed by filtration, and the
absorbance was measured at 253 nm in order to quantify the
initial amount of drug in the system. Subsequently, the
appropriate stimuli were applied as described above for the
DLS degradation study. The samples were then each placed in
an individual 20 mL vial equipped with a small bar magnet,
stirred at low rpm, and kept in a 37 °C oven for the duration of
the study. At specified time points, each sample was centrifuged
for 3 min at 2800g to separate the precipitated drug from the
suspended particles. The suspension was decanted back into
the initial vial and placed back into the oven, while the pellet
was dissolved in 1 mL of acetonitrile and the absorbance at 253
nm measured to quantify the amount of drug that had been
released and consequently precipitated (appropriate dilutions
performed to ensure an absorbance less than 1.0). This amount
was compared to the initial amount of encapsulated drug in
order to determine the percentage of released drug. 1H NMR
spectra of the pellets were obtained at 400 MHz in CD3CN at 4
and 24 h, to confirm the identity of the precipitated material.
In Vitro Cell Toxicity Study. Dulbecco’s Modified Eagle
Medium (DMEM) with 4.5 g/L of D-glucose and 110 mg/L of
sodium pyruvate was obtained from Gibco. Penicillin-
streptomycin (Pen Strep, 10000 U/mL), L-glutamine, fetal
bovine serum (FBS), and trypsin-EDTA (0.25%) were obtained
from Gibco. The MDA-MB-231 cells were cultured in DMEM
with 10 vol % FBS, 100 units/mL of Pen Strep, and 2 mM L-
glutamine added in an atmosphere of 5% CO2 at 37 °C. The
cells were seeded in a 96-well plate (Corning Flat Bottom
Plate) at a density of 10 000 cells/well and allowed to adhere
for 24 h. The medium was then aspirated and replaced with
varying concentrations of particles, just medium as a negative
control, or sodium lauryl sulfate as a positive control. For
nontriggered samples, the cells were incubated for 48 h with the
materials. For irradiated PEtG−NVOC samples, the cells were
incubated for 24 h with the particles and irradiated for 15 min
with two 360 nm light-emitting diode (LED) flashlights
(Convoy S2+, 90 mMW/cm2 at a distance of 5 cm), and
then the cells were incubated for a further 24 h. For GSH-
triggered PEtG-disulfide samples, the cells were incubated for
24 h with the particles, and then 10 mM GSH was added. The
cells were incubated for an additional 24 h. Controls did not
involve stimuli. The medium was then aspirated and replaced
with 100 μL of fresh medium containing 0.5 mg/mL of MTT
reagent and allowed to react for 4 h in the incubator. After 4 h
the plate was removed, and the MTT reagent solution was
aspirated. An amount of 50 μL of dimethyl sulfoxide was added
to each well to solubilize the purple crystals. The plate was then
placed in a plate reader (Tecan Infinite M1000 Pro), and the
absorbance at 540 nm was measured to quantify the relative
metabolic activities of the cells.
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